Elanco Animal Health Inc (ELAN): Results of Operations and Financial Condition
Elanco Animal Health Inc (ELAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Second Quarter 2026 Results Raising Full Year Outlook an
How this was made
The 30-second read
Why it matters
The company raised full-year revenue, adjusted EBITDA, adjusted EPS, and improved the year-end net leverage ratio target, indicating stronger operating momentum and balance-sheet deleveraging.
Market read
A same-day guidance raise across top-line growth, profitability, and leverage is a direct catalyst for ELAN valuation and positioning.
What to watch
The release highlights adjusted metrics; traders may want to scrutinize the drivers of net leverage improvement and any one-time items behind reported net income volatility.
Elanco Animal Health Reports Second Quarter 2026 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target
Revenue grew 10% on a reported basis and 8% on an organic constant currency basis, adjusted EBITDA rose 21%, adjusted EBITDA margin expanded to 21.2%, and the company raised full-year revenue, adjusted EBITDA, and adjusted EPS guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total RevenueGAAP | $1,368 million | – | 10% |
| Organic constant currency revenue growthother | 8% | – | – |
| Gross ProfitGAAP | $798 million | – | 12% |
| Gross margin percentageGAAP | 58.3% | – | an increase of 80 basis points |
| Adjusted Gross Profitnon-GAAP | $789 million | – | – |
| Adjusted gross margin percentagenon-GAAP | 58.1% | – | an increase of 80 basis points |
| Total operating expensesGAAP | $541 million | – | 10% |
| Marketing, selling and administrative expensesGAAP | $449 million | – | 12% |
| Research and development expensesGAAP | $92 million | – | remained flat |
| Asset impairment, restructuring and other special chargesGAAP | $9 million | – | – |
| Reported net interest expenseGAAP | $59 million | – | an increase of $11 million |
| Adjusted net interest expensenon-GAAP | $44 million | – | an increase of $6 million |
| Reported effective tax rateGAAP | 3.3% | – | – |
| Adjusted effective tax ratenon-GAAP | 17.8% | – | – |
| Reported Net IncomeGAAP | $54 million | – | 391% |
| Adjusted Net Incomenon-GAAP | $174 million | – | 31% |
| Reported EPSGAAP | $0.11 | – | 450% |
| Adjusted EPSnon-GAAP | $0.34 | – | 31% |
| Adjusted EBITDAnon-GAAP | $288 million | – | 21% |
| Adjusted EBITDA Marginnon-GAAP | 21.2% | – | – |
| Cash provided by operationsGAAP | $277 million | – | – |
| Net leverage ratioother | 3.1x adjusted EBITDA | a decrease of 0.5x | – |
| Royalty revenue sold to a third partyGAAP | $9 million | – | – |
| Advantage Family revenueGAAP | $154 million | – | – |
| Seresto revenueGAAP | $117 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Pet HealthThe year-over-year volume increase of 9% in the second quarter was primarily driven by strong demand for Zenrelia and Credelio Quattro. The 2% increase from price was in line with the company's expectation. | $718 million | – | 12% |
| Farm AnimalSecond quarter volumes were up 3%, primarily driven by strong demand across our global ruminant portfolio. Farm animal organic constant currency revenue growth included a 2% increase from price. | $633 million | – | 9% |
| CattleGlobal ruminants was Elanco's fastest growing species, up 12% in the quarter on an organic constant currency basis or 17% including AHV International and FX, as innovation fortified the company's beef and dairy portfolio. | $313 million | – | 17% |
| Poultry | $223 million | – | 4% |
| Swine | $97 million | – | (3)% |
| Contract Manufacturing and OtherPrimarily represents revenue from arrangements in which we manufacture products on behalf of a third party and royalty revenue. | $17 million | – | 13% |
Full Year 2026 and Third Quarter 2026 outlook
- RevenueFull Year 2026: $5,090 to $5,140; Third Quarter 2026: $1,195 to $1,220
- Gross marginFull Year 2026 adjusted gross margin: 55.2% to 55.6%
- NoteFull Year 2026 Adjusted EBITDA: $1,010 to $1,035
- NoteFull Year 2026 Adjusted Earnings per Share: $1.10 to $1.16
- NoteFull Year 2026 revenue growth excluding the impacts of foreign exchange rates, the AHV International acquisition, and royalty revenue sold to a third party: 6% to 7%
- NoteFull Year 2026 anticipated tailwind to revenue from the favorable impact of foreign exchange rates compared to prior year: approximately $60 million
- NoteFull Year 2026 adjusted gross margin improvement versus 2025: 50 basis points
- NoteFull Year 2026 innovation revenue target: $1.25 billion
- NoteFull Year 2026 year-end net leverage ratio target: approximately 3.0x Adjusted EBITDA
- NoteThird Quarter 2026 Adjusted EBITDA: $200 to $215
- NoteThird Quarter 2026 Adjusted Earnings per Share: $0.19 to $0.22
- NoteThird Quarter 2026 anticipated foreign exchange impact compared to prior year: neutral
What drove it
- Pet Health organic constant currency growth was 11%, supported by a 9% year-over-year volume increase and a 2% increase from price.
- Farm Animal organic constant currency growth was 5%, with volumes up 3% and a 2% increase from price.
- Zenrelia achieved blockbuster status July YTD and was the single largest contributor to global Elanco growth, closely followed by Credelio Quattro.
- Global ruminants was Elanco's fastest growing species, up 12% in the quarter on an organic constant currency basis or 17% including AHV International and FX.
- Reported and adjusted gross-margin expansion was primarily driven by favorable mix from strong U.S. Pet Health performance and increased pricing.
- Adjusted EBITDA guidance reflects savings from the Elanco Ascend initiative, incremental strategic investments in global innovation-product launches, and advancement of the R&D pipeline.
Concerns
- Swine revenue declined (3)% and organic constant currency growth was (4)%.
- Higher inventory costs due to inflation partially offset gross-margin expansion.
- Marketing, selling and administrative expenses increased 12%, driven by strategic investments in global new-product launches and higher compensation expense.
- Reported net interest expense increased by $11 million, principally due to imputed interest on the liability for sale of future revenue and interest expense related to the corporate headquarters finance lease.
- Asset impairment, restructuring and other special charges were $9 million, compared to $1 million in the prior-year period.
What to watch
- Delivery against full-year revenue guidance of $5,090 to $5,140 and adjusted EBITDA guidance of $1,010 to $1,035.
- Third-quarter revenue guidance of $1,195 to $1,220, adjusted EBITDA guidance of $200 to $215, and adjusted EPS guidance of $0.19 to $0.22.
- Progress toward the year-end net leverage ratio target of approximately 3.0x Adjusted EBITDA.
- The contribution of Zenrelia, Credelio Quattro, and Befrena to growth and market-share gains.
- Elanco Ascend productivity progress toward $200 million to $250 million in adjusted EBITDA net savings by 2030.
Balance sheet and cash flow
- Cash provided by operations was $277 million in the second quarter of 2026, compared to cash provided by operations of $237 million in the second quarter of 2025.
- As of June 30, 2026, Elanco’s net leverage ratio was 3.1x adjusted EBITDA, a decrease of 0.5x compared to December 31, 2025.
Analysis
Elanco reported a strong second quarter, with total revenue of $1,368 million, up 10% on a reported basis and 8% on an organic constant currency basis. Pet Health was the principal growth engine, rising 12% reported and 11% on an organic constant currency basis, while Farm Animal grew 9% reported and 5% on an organic constant currency basis. Management attributed Pet Health volume growth to demand for Zenrelia and Credelio Quattro, while Farm Animal volume growth was driven by the global ruminant portfolio.
Profitability improved materially. Gross profit increased 12% to $798 million, reported gross margin reached 58.3%, and adjusted gross margin reached 58.1%, with both margins increasing 80 basis points. Favorable U.S. Pet Health mix and pricing were the stated sources of expansion, partly offset by higher inventory costs due to inflation. Adjusted EBITDA increased 21% to $288 million and adjusted EBITDA margin was 21.2%, compared with 19.2% in the prior-year period.
The company continued to invest behind its portfolio. Marketing, selling and administrative expenses rose 12% to $449 million, driven by global launches of new products and higher compensation expense, while research and development expenses remained flat at $92 million. Reported net interest expense increased by $11 million to $59 million, principally reflecting imputed interest on the liability for sale of future revenue and finance-lease interest, although lower average debt balances partially offset those items. Cash provided by operations increased to $277 million, and net leverage improved to 3.1x adjusted EBITDA.
Management raised full-year revenue guidance to $5,090 to $5,140, adjusted EBITDA guidance to $1,010 to $1,035, and adjusted earnings per share guidance to $1.10 to $1.16. The full-year adjusted gross-margin outlook is 55.2% to 55.6%, with an expected 50-basis-point improvement versus 2025. The company also raised its innovation revenue target to $1.25 billion and improved its year-end net leverage ratio target to approximately 3.0x Adjusted EBITDA.
Key execution issues are the pace of innovation-product adoption, continued margin delivery while funding launches and R&D, and deleveraging toward the stated year-end target. Zenrelia, Credelio Quattro, and Befrena are central commercial indicators, while Swine remained a weak point, with revenue down (3)% and organic constant currency growth of (4)% in the quarter.
Management, verbatim
Organic constant currency revenue growth of 8% was led by U.S. Pet Health and U.S. Farm Animal each up 11%. We saw strong contributions from both price and volume, as consumer demand for our basket of innovation drove market share gains and stabilized our base business.
Jeff Simmons, President and CEO of Elanco
Zenrelia — our newest blockbuster — was the single largest contributor to global Elanco growth, closely followed by Credelio Quattro.
Jeff Simmons, President and CEO of Elanco
Our faster than expected margin expansion includes good early progress on our Elanco Ascend productivity initiatives, on track to $200 million to $250 million in adjusted EBITDA net savings by 2030.
Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health
Not in the filing
stated, not guessed- Prior-quarter revenue, segment revenue, profitability, EPS, cash flow, and margin comparisons.
- Cash balance as of June 30, 2026.
- Total debt balance as of June 30, 2026.
- Free cash flow.
- Share repurchases, dividends, and other capital-return amounts.
- Absolute prior-year amounts for total operating expenses, marketing, selling and administrative expenses, research and development expenses, reported net interest expense, adjusted net interest expense, adjusted net income, and adjusted gross profit.
- Full-year operating-expense guidance and tax-rate guidance.
- Prior release outlook section required for a formal actual-versus-prior-guidance comparison.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K with Elanco’s Q2 2026 results and updated FY 2026 guidance, including an innovation revenue target change.
Ticker impact
Elanco reported Q2 2026 results and raised full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and net leverage guidance.
Likely positive near-term bias as guidance increases across revenue, profitability, and leverage metrics.
The filing includes explicit upward revisions to multiple FY 2026 guidance lines, plus Q2 performance metrics (revenue growth, adjusted EBITDA, margin, and net leverage).
Market effects
Animal health peers may see read-across on demand durability and margin expansion if investors treat the guidance raise as sector-strength signal.
US Pet Health strength and ruminants growth could influence sentiment toward North American animal health distributors and clinic-channel names.
International growth contributions (including Europe and other regions cited) support a broader global demand narrative for companion-animal and protein markets.
Counterpoint
Guidance raises could already be partially priced in, and margin expansion may depend on execution and mix that could normalize later.
Key entities
- companyElanco Animal Health Incorporated
NYSE-listed animal health company reporting Q2 2026 results and raising FY 2026 guidance.
- productZenrelia
Elanco’s newest blockbuster cited as the largest contributor to global growth, with clinic penetration and market share gains.
- productCredelio Quattro
Broad-spectrum product cited for accelerated share gains and clinic penetration.
- productBefrena
Product shipment and ramp details cited for US clinic distribution.
